Viking’s new dual GLP-1R/GIPR agonist expected to start Phase III trials soon
VK2735 could potentially become a direct competitor to Eli Lilly's Mounjaro.
![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Mountjaro-CW-feat-img.jpg)
VK2735 could potentially become a direct competitor to Eli Lilly's Mounjaro.
The pivotal study is evaluating DeepView’s algorithms and their ability to assess burn healing potential.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Hyperfine’s portable MRI shows promise in stroke detection
Impact of AI on metabolic disorder clinical trials
AB Science touts positive Phase II Covid-19 data for masitinib
Robots in surgery – a clinical trial snapshot